The Vanguard Group, Inc. recently announced the acquisition of new stake in Hims & Hers Health Inc (NYSE:HIMS). The institutional investor has increased its shareholding in the Consumer Defensive company by 3.05% to 13.75 million shares with purchase of 0.41 million shares. This fresh investment now brings its stake to 6.79% valued currently at $82.25 million. In addition, BlackRock Fund Advisors raised its holdings by 0.5 million to 8.63 million shares. And Marshall Wace LLP has lifted its position by 5.10% or 0.3 million shares – to 6.18 million shares.
With over 4.44 million Hims & Hers Health Inc (HIMS) shares trading Tuesday and a closing price of $8.44 on the day, the dollar volume was approximately $37.45 million. The shares have shown a negative half year performance of -6.64% and its price on 12/12/23 lost nearly -4.09%. Currently, there are 200.05M common shares owned by the public and among those 135.82M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 10 analysts who have offered their price forecasts for HIMS have a consensus price objective of $10.25. The analysts have set the share’s price value over the next 12 months at a high of $15.00 and a low of $7.00. The average price target is 17.66% above its recent price level and a downside to the estimated low will see the stock lose -20.57% over that period. But an upside of 43.73% will see the stock hit the forecast high price target while median target price for the stock is $10.50.
Insiders at the company have transacted a total of 197 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 83 of these insider trades were purchases, accounting for 3,396,718 shares. Insider sales of the common stock occurred on 114 occasions, with total insider shares sold totaling 12,883,451 shares.
The top 3 mutual fund holders in Hims & Hers Health Inc are Vanguard Total Stock Market ETF, Vanguard Small Cap Index Fund, and iShares Russell 2000 ETF. Vanguard Total Stock Market ETF owns 4.52 million shares of the company’s stock, all valued at over $27.03 million. Vanguard Small Cap Index Fund bought 25582.0 shares to see its total holdings expand to 3.67 million shares valued at over $21.94 million and representing 1.81% of the shares outstanding. iShares Russell 2000 ETF sold 28379.0 shares to bring its total holdings to over 2.83 million shares at a value of $16.91 million. iShares Russell 2000 ETF now owns shares totaling to 1.40% of the shares outstanding.
Shares of Hims & Hers Health Inc (NYSE: HIMS) opened at $8.84, up $0.04 from a prior closing price of $8.80. However, the script later moved the day high at 8.84, down -4.09%. The company’s stock has a 5-day price change of -4.52% and 32.70% over the past three months. HIMS shares are trading 31.67% year to date (YTD), with the 12-month market performance up to 18.21% higher. It has a 12-month low price of $5.65 and touched a high of $12.34 over the same period. HIMS has an average intraday trading volume of 2.53 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 2.45%, 19.55%, and 0.39% respectively.
Institutional ownership of Hims & Hers Health Inc (NYSE: HIMS) shares accounts for 39.52% of the company’s 200.05M shares outstanding. Mutual fund holders own 20.87%, while other institutional holders and individual stakeholders account for 36.12% and 20.68% respectively.
It has a market capitalization of $1.79B and a beta (3y monthly) value of 0.78. The earnings-per-share (ttm) stands at -$0.17. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.01% over the week and 4.18% over the month.
Analysts forecast that Hims & Hers Health Inc (HIMS) will achieve an EPS of $Himax Technologies, Inc. for the current quarter, $5.44 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $Direxion Daily S&P 500 High Bet while analysts give the company a high EPS estimate of $Hingham Institution for Savings. Comparatively, EPS for the current quarter was $GraniteShares HIPS US High Inco a year ago. Earnings per share for the fiscal year are expected to increase by 59.91%, and 74.99% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 10 brokerage firm advisors rate Hims & Hers Health Inc (HIMS) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 5 Wall Street analysts polled rate the stock as a buy, while 5 of the 10 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the HIMS, a number of firms have released research notes about the stock. Imperial Capital stated their In-line rating for the stock in a research note on December 07, 2023, with the firm’s price target at $9.
